RET and thyroid gland carcinoma: Selpercatinib was found to have robust and durable efficacy with a favorable safety profile in patients with advanced or metastatic RET-driven, treatment-naive, and previously treated cancers, regardless of prior therapy.5,6 Notable activity was achieved in treatment-naive patients.5,6 As a result, selpercatinib is approved in multiple countries for the treatment of RET-altered lung or thyroid cancers.7,8